Stage IV Nasopharyngeal Carcinoma Clinical Trial
Official title:
Olfactory Training For Post Radiation Olfactory Loss In Patients With Paranasal Sinus and Nasopharyngeal Carcinoma
This randomized phase I trial studies how well olfactory training works in improving sense of smell after radiation therapy in patients with paranasal sinus or nasopharyngeal cancer. Olfactory training may improve smell function after radiation therapy in patients with paranasal sinus or nasopharyngeal cancer.
PRIMARY OBJECTIVES:
I. To evaluate the effect of olfactory training on olfactory function in patients with
paranasal sinus and nasopharyngeal carcinoma suffering from olfactory loss after radiation.
SECONDARY OBJECTIVES:
I. To evaluate the possible effect of olfactory training on quality of life in patients with
paranasal sinus and nasopharyngeal carcinoma suffering from olfactory loss after radiation.
II. To study rate and severity of olfactory dysfunction after radiation therapy in patients
with paranasal sinus or nasopharyngeal carcinoma.
III. To evaluate the possible preventive effect of olfactory training on olfactory
dysfunction in patients with paranasal sinus and nasopharyngeal carcinoma who will undergo
radiation therapy.
OUTLINE: Patients are randomized to 1 of 2 arms. Arm I: Patients undergo olfactory training
by smelling 4 essential oils in vials (rose, lemon, clove, and eucalyptus) over 15 seconds
each, twice daily for 12 weeks.
Arm II: Patients undergo sham training by smelling canola oil in 4 vials over 15 seconds
each, twice daily for 12 weeks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02538510 -
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT01616849 -
Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
Recruiting |
NCT01655628 -
GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
Withdrawn |
NCT04231864 -
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
|
Phase 2 | |
Recruiting |
NCT03044743 -
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
|
Phase 1/Phase 2 |